Promising cocktail of drugs targets rare blood cancer
NCT ID NCT07574528
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of three drugs (sintilimab, pegaspargase, and selinexor) followed by radiation in 47 people with newly diagnosed stage I/II extranodal NK/T-cell lymphoma, a rare blood cancer. The goal is to see how many patients achieve complete remission after treatment. It is an early-phase trial without a placebo group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sintilimab, pegaspargase, selinexor, and radiotherapy
- What this could lead to
- If successful, this combination could become a new first-line treatment option for early-stage NK/T-cell lymphoma, potentially improving response rates and reducing relapse.
- What could go wrong
- This is a small, early-phase (Phase 2) trial with only 47 participants and no comparison group, so results may not be definitive. The drug combination may cause significant side effects, and not all patients may respond.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NKTCL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, 广东省 - Guangdong Sheng, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.